TV News LIES

Eileen Schoch traveled to her mother's funeral in Asheville, N.C. and found the hotel room — the one she'd called about in advance — wasn't accessible as promised.

Schoch, who uses a wheelchair after two strokes, couldn't use the room's toilet without assistance from her husband or daughter. The grab bars were in the wrong place. She couldn't get into the shower because it had a door too narrow for her wheelchair. She got sponge baths for three days.

Nor could she reach the tall bed from her wheelchair. The hotel gave her an uncomfortable cot, instead.

"You feel that you're treated as a second-class citizen. And you don't count," says Schoch, a retired educator from Schenectady, N.Y.. "And it's not a nice feeling."

Schoch said she considered switching hotels, but she wanted to be close to other family members. After all, they'd picked that hotel because she'd chosen it first. The family brought business to the hotel, booking four rooms for three days.

Schoch asks: "After that experience, who would want to travel?"

More...

US regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

The US Food and Drug Administration’s approval handed drugmaker Novo Nordisk an edge over rihttps://www.theguardian.com/us-news/2025/dec/22/us-regulators-approve-wegovy-weight-loss-pillval Eli Lilly in the race to market an obesity pill. Lilly’s oral drug, orforglipron, is still under review.

Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of fullness.

In recent years, Novo Nordisk’s injectable Wegovy and Lilly’s Zepbound have revolutionized obesity treatment globally and in the US, where 100 million people have the chronic disease.

The Wegovy pills are expected to be available within weeks, company officials said. Availability of oral pills to treat obesity could expand the booming market for obesity treatments by broadening access and reducing costs, experts said.

About one in eight Americans have used injectable GLP-1 drugs, according to a survey from KFF, a nonprofit health policy research group. But many more have trouble affording the costly shots.

“There’s an entire demographic that can benefit from the pills,” said Dr Fatima Cody Stanford, a Massachusetts General Hospital obesity expert. “For me, it’s not just about who gets it across the finish line first. It’s about having these options available to patients.”

More...

Dr. Kade Goepferd watched the Trump administration's moves on Thursday to ban gender-affirming care for transgender youth with "a mix of sadness and frustration."

Goepferd, who is the founder of Children's Minnesota Gender Health Program, says that for the medical community, nothing has changed about the evidence supporting gender-affirming care that could justify the government's actions.

"There's a massive propaganda and disinformation campaign that is selectively targeting this small population of already vulnerable kids and their families," Goepferd says.

Federal health officials said many times at Thursday's announcement that their actions were driven by science and evidence, not politics or ideology. They frequently praised a report published by the Department of Health and Human Services in November. It concluded that clinicians who provide medical care to help youth transition have failed their patients and emphasized the benefits of psychotherapy as an alternative.

More...

With subsidies for Affordable Care Act (ACA) health insurance set to expire, Americans who rely on them will probably switch to plans with lower monthly premiums and high deductibles or decide not to purchase any coverage, which will have a serious and damaging impact on the entire sector, according to healthcare policy experts.

The average amount ACA plan enrollees pay annually for premiums is estimated to more than double, from an average of $888 this year to $1,904 in 2026, according to a KFF analysis.

That will then have economic downstream effects, including for rural hospitals and people who have employer-sponsored health insurance, according to the experts.

With “a significant portion of people dropping their marketplace coverage and being uninsured, it doesn’t just impact them, it impacts everyone”, said Emma Wager, a senior policy analyst for KFF’s program on the Affordable Care Act (ACA).

More...

A California jury on Friday awarded $40m to two women who said Johnson & Johnson’s baby powder was to blame for their ovarian cancer.

The jury in Los Angeles superior court awarded $18m to Monica Kent and $22m to Deborah Schultz and her husband after finding that Johnson & Johnson knew for years its talc-based products were dangerous but failed to warn consumers.

Erik Haas, Johnson & Johnson’s worldwide vice-president of litigation, said in a statement the company plans to “immediately appeal this verdict and expect to prevail as we typically do with aberrant adverse verdicts”.

A spokesperson for the plaintiffs did not immediately respond to a request for comment.

Kent was diagnosed with ovarian cancer in 2014, according to court records. Schultz was diagnosed in 2018. Both women are California residents who say they used J&J’s baby powder after bathing for 40 years. Their treatments for ovarian cancer have involved major surgeries and dozens of rounds of chemotherapy, they testified at the trial.

In closing arguments that Reuters viewed on Courtroom View Network, Andy Birchfield, an attorney for the women, told the jury that Johnson & Johnson knew as far back as the 1960s that its product could cause cancer.

More...

Connecticut, Georgia, Idaho, Massachusetts, Michigan, Rhode Island, South Carolina, Texas and Puerto Rico also saw an increase in the spread of the virus, landing them in the “moderate” tier.

New York City, which reports as a separate jurisdiction from the rest of the state, moved into the most severe category for “very high” flu activity.

Much of this season’s flu activity is being driven by a new variant of influenza called subclade K. The subclade is a type of H3N2 influenza, which has historically caused more hospitalizations and deaths.

It’s not too late to boost your protection against the virus. “CDC recommends that every 6 months and older who has not yet been vaccinated this season get an annual influenza (flu) vaccine,” the agency said Friday.

The CDC said it has distributed 127 million doses so far.

More...